CATHERINE M. D'ARCANGUES, M.D., Ph.D.; SISSAY AWOKE, M.D.; GEORGE D. LAWRENCE, M.D.
In 1966, during cholecystectomy for cholecystolithiasis, a 56-year-old man was found to have islet-cell carcinoma metastatic to the liver; his fasting serum glucose level was normal. In 1971, he developed peptic ulcer disease and symptoms of fasting hypoglycemia; inappropriate secretion of insulin was shown. His primary pancreatic tumor was removed in 1973. During the next 9 years, his liver metastases continued to grow and his fasting serum glucose level was maintained at 35 to 116 mg/dL with diazoxide and hydrochlorothiazide therapy. In 1982, he developed clinical evidence of the glucagonoma syndrome, with glucagon levels between 4000 and 11 000 pg/mL. Since then, his fasting serum glucose level has been maintained at 58 to 119 mg/dL without medication. This patient has survived 17 years with a malignant insulinoma and without islet-cell chemotherapy. His course shows that malignant insulinomas may secrete other peptide hormones that can induce various clinical syndromes.
Learn more about subscription options.
Register Now for a free account.
D'ARCANGUES CM, AWOKE S, LAWRENCE GD. Metastatic Insulinoma with Long Survival and Glucagonoma Syndrome. Ann Intern Med. 1984;100:233-235. doi: 10.7326/0003-4819-100-2-233
Download citation file:
Published: Ann Intern Med. 1984;100(2):233-235.
Gastroenterology/Hepatology, Gastrointestinal Cancer, Hematology/Oncology, Pancreatic Cancer, Pancreatic Disease.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only